该收购案始于今年年初，过程几经波折。1月10日，Quanteri x宣布收购Akoya Biosciences，根据协议，以1股Akoya股票置换0.318股 Quanteri x股票。收购目的是，一、将Akoya的空间空间生物学与其基于血液的超灵敏蛋白检测技术可以形成技术互补；二、扩展应用领域， 从原来的神经学拓展到肿瘤学领域；三、借助Akoya的合作伙伴，推动其产品进入临床市场；四、通过大幅成本节约，加速实现盈利。该交易 将产生约4000万美元的年度成本协同效应，其中2000万美元预计将在交易结束后的第一年内实现，预计2026年将实现正向现金流。 之后，由于Quanteri x股东之一基金公司Kent Lake PR LLC对收购提出反对意见，让收购案一度出现不确定性。双方在4月对合并协议进行 了修订。修订后，以1股Akoya股票置换0.1461股Quanteri x股票+0.38美元现金。 关于Quanteri x Quanteri x Corporation（纳斯达克代码：QTRX）是一家专注于超灵敏生物标志物检测的生命科学公司，总部位于美国马萨诸塞州比勒里卡 （ Bi l lerica ） ， 成 ...

First Quarter 2025 Earnings May 12, 2025 " Legal Information IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. ("Akoya") by Quanterix (the "Merger"), Quanterix will file with the U.S. Securities and Exchange Commission (the "SEC") a post-effective amendment to its registration statement on Form S-4 (as so amended, the "Registration Statement"), which will contain a preliminary proxy statement of Akoya and a preliminary prospectus of Quanterix (the "Proxy ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company has shown significant growth in its respiratory multi-detection products, with a revenue increase of 29.99% year-on-year, reaching 621 million yuan in 2024. The net profit attributable to the parent company also increased by 41.92% to 247 million yuan [6][8] - The company is expanding its product offerings in Alzheimer's disease (AD) detection through a strategic partnership with Quanterix, leveraging advanced digital immunoassay technology for early diagnosis and screening [7][8] - The company is expected to achieve steady revenue and profit growth in the coming years, with projected revenues of 729 million yuan in 2025, 828 million yuan in 2026, and 921 million yuan in 2027, reflecting year-on-year growth rates of 17.3%, 13.6%, and 11.3% respectively [8] Financial Summary - In 2024, the company achieved a total revenue of 621 million yuan, with a year-on-year growth of 30.0%. The net profit attributable to the parent company was 247 million yuan, with a net profit growth of 41.9% [11] - The projected financials for 2025 to 2027 indicate a consistent growth trajectory, with net profits expected to reach 280 million yuan in 2025, 325 million yuan in 2026, and 390 million yuan in 2027, corresponding to growth rates of 13.5%, 15.9%, and 20.1% respectively [11] - The company's gross margin is projected to remain strong, with estimates of 80.1% in 2024, 83.8% in 2025, and gradually declining to 79.3% by 2027 [11]